Ingredient or product comparison
GHK-Cu vs. Similar Peptides: Side Effect Comparison
Comparing GHK-Cu's side effect profile with related peptides provides important context for risk-benefit assessment, though direct head-to-head safety studies remain limited. Most comparative data derives from separate studies using similar populations and met
This source-based comparison does not add ratings or recommend a winner.
- Comparing GHK-Cu's side effect profile with related peptides provides important context for risk-benefit assessment, though direct head-to-head safety studies remain limited. Most comparative data derives from separate studies using similar populations and methodologies.[1]
- GHK vs. Copper Gluconate shows distinct safety profiles despite both containing copper. Copper gluconate demonstrates higher gastrointestinal side effect rates (15-20% nausea, 8-12% abdominal discomfort) compared to topical GHK-Cu's predominantly dermatological reactions.[2] However, GHK-Cu shows superior skin tolerance with 40-50% fewer local reactions than equivalent copper concentrations from inorganic sources.
- GHK-Cu vs. Other Copper Peptides reveals relatively favorable tolerability for the tripeptide complex. Copper-histidine complexes demonstrate 20-30% higher rates of contact sensitization, while copper-methionine shows increased photosensitivity reactions affecting 8-10% of users versus 2-3% for GHK-Cu.[3]
- Comparison with Growth Factor Peptides like IGF-1 LR3 and BPC-157 shows GHK-Cu's lower systemic absorption reducing injection site reaction severity. While growth factor peptides may cause injection site reactions in 30-40% of users, GHK-Cu topical applications maintain local reaction rates below 15% in most studies.[4]
- GHK-Cu
- Copper chelation, collagen synthesis
- Mild erythema (5-8%)
- 10-15%
- <0.1%
- Copper accumulation risk
- Copper Gluconate
- Copper supplementation
- GI upset (15-20%)
- Higher systemic absorption
- BPC-157
- Tissue healing
- Injection site pain (25-30%)
- 30-40%
- No metal toxicity concerns
- IGF-1 LR3
- Growth promotion
- Hypoglycemia (10-15%)
- 35-45%
- 1-2%
- Metabolic effects predominate
- Melanotan II
- Melanogenesis
- Nausea (40-50%)
- 15-20%
- Systemic effects more common
- The comparison reveals GHK-Cu's relatively favorable local tolerability profile, though unique copper-related risks distinguish it from purely peptide-based compounds. For detailed comparisons, see our peptide comparison guide.